New directions in the management of chemotherapy-induced neutropenia: Risk models, special populations, and quality of life

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 13, 2003, Pages 18-23

  Ozer, Howard ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; HUMAN; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; RISK FACTOR;

EID: 0141590563     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00315-4     Document Type: Article

References (39)

1. Kuderer NM, Cosler L, Crawford J, et al: Cost and mortality associated with febrile neutropenia in adult cancer patients. Proc Am Soc Clin Oncol 21:250a, 2002 (abstr 998)
2. Gandhi SK, Arguelles L, Boyer JG: Economic impact of neutropenia and febrile neutropenia in breast cancer: Estimates from two national databases. Pharmacotherapy 21:684-690, 2001
3. Schuette HL, Tucker TC, Brown ML, et al: The costs of cancer care in the United States: Implications for action. Oncology (Huntingt) 9:19-22, 1995 (suppl 11)
4. Fortner B, Solshek B, Tauer KW, et al: Chemotherapy-induced neutropenia (CIN) is associated with lower quality of life in patients with cancer. Ann Oncol 13:174, 2002 (suppl 15) (abstr)
5. Okon TA, Fortner BV, Schwartzberg L, et al: Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN). Proc Am Soc Clin Oncol 21:275b, 2002 (abstr 2920)
6. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558-3585, 2000
7. Calhoun EA, Chang C-H, Welshman EE, et al: A neutropenia-specific quality of life instrument: Rationale for the development of the FACT-N. Proc Am Soc Clin Oncol 21: 375a, 2002 (abstr 1498)
8. Lyman GH: Balancing the benefits and costs of colony-stimulating factors: A current perspective. Semin Oncol 30: 10-17, 2003 (suppl 13)
9. Lyman GH, Lyman CG, Sanderson RA, et al: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-493, 1993
10. Lyman GH, Kuderer N, Greene J, et al: The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer 34:1857-1864, 1998
11. Cosler LE, Calhoun EA, Agboola O, et al: Impact of indirect cost estimates on risk thresholds for G-CSF prophylaxis against neutropenic complications in cancer chemotherapy. Society of Health-System Pharmacists, New Orleans, LA, December 2, 2001, Poster P669E
12. Gomez H, Hidalgo M, Casanova L, et al: Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis. J Clin Oncol 16:2065-2069, 1998
13. Caggiano V, Stolskek B, Delgado D, et al: First and all cycle febrile neutropenia hospitalizations (FNH) and costs in intermediate grade non-Hodgkins lymphoma (IGL) patients on standard-dose CHOP therapy. Blood 98:431a, 2001 (abstr 1810)
14. Meza L, Baselga J, Holmes FA, et al: Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 21:255b, 2002 (abstr 2840)
15. Silber JH, Fridman M, DiPaola RS, et al: First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 16: 2392-2400, 1998
16. Rivera E, Erder MH, Moore TD, et al: Targeted filgrastim support in patients with early-stage breast carcinoma: Toward the implementation of a risk model. Cancer 98:222-228, 2003
17. Lininger L, Crawford J, Dale D, et al: Predicting risk of neutropenic complications: A point-of-care assessment tool. Proc Am Soc Clin Oncol 20:411a, 2001 (abstr 1640)
18. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, et al: A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 37:351-360, 2000
19. Wilson-Royalty M, Lawless G, Palmer C, et al: Predictors for chemotherapy-related severe or febrile neutropenia: A review of the clinical literature. J Oncol Pharm Pract 7:1-7, 2001
20. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 5:224-237, 2000
21. Morrison VA, Picozzi V, Scott S, et al: The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: A risk factor analysis. Clin Lymphoma 2:47-56, 2001
22. Agboola O, Crawford J, Dale DC, et al: Risk models for neutropenic complications associated with breast cancer adjuvant therapy. Proc Am Soc Clin Oncol 21:66a, 2002 (abstr 261)
23. Yancik R, Ries LAG: Aging and cancer in America: Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14:17-23, 2000
24. US Census Bureau: Available at: http://www.census.gov/ population/www/projections/natsum.html (accessed May 9, 2003)
25. Edwards BK, Howe HL, Ries LA, et al: Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 94: 2766-2792, 2002
26. Balducci L, Carreca I: The role of myelopoietic growth factors in managing cancer in the elderly. Drugs 62:47-63, 2002 (suppl 1)
27. Balducci L, Yates J: General guidelines for the management of older patients with cancer. Oncology (Huntingt) 14: 221-227, 2000
28. Jacobson JO, Grossbard M, Shulman LN, et al: CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: A dose-intensity analysis. Clin Lymphoma 1:211-217, 2000
29. Vose JM, Armitage JO, Weisenburger DD, et al: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 6:1838-1844, 1988
30. Chrischilles E, Delgado DJ, Stolshek BS, et al: Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 9:203-211, 2002
31. Balducci L, Repetto L: Increased risk of myelotoxicity in elderly patients with cancer: The case for routine prophylaxis with colony-stimulating factor beginning in the first cycle of chemotherapy. Cancer 2003 (in press)
32. Zinzani PL, Pavone E, Storti S, et al: Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 89:3974-3979, 1997
33. Zagonel V, Babare R, Merola MC, et al: Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 5:127-132, 1994 (suppl 2)
34. Bertini M, Freilone R, Vitolo U, et al: P-VEBEC: A new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 5:895-900, 1994
35. Björkholm M, Osby E, Hagberg H, et al: Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma. Blood 94: 599a, 1999 (abstr 2655)
36. Lyman GH, Balducci L, Agboola YL: Use of colony-stimulating factors in the elderly cancer patient. Oncology Spectrums 2:414-421, 2001
37. Glaspy J, Hackett J, Flyer P, et al: Febrile neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities. Blood 98:432a, 2001 (abstr 1812)
38. Lyman GH, Kuderer NM: Filgrastim in patients with neutropenia: Potential effects on quality of life. Drugs 62:65-78, 2002 (suppl 1)
39. Erder MH, Fridman M, Weaver C: Cancer patients (CPs) perspectives about the impact of febrile neutropenia morbidity (FNM) on their well being (WB) and preferences for filgrastim treatment vs dose reduction to prevent FN: An internet survey. Proc Am Soc Clin Oncol 20:210b, 2001 (abstr 2589)